Salivary duct stone
Methodology & AI Transparency ⓘ
Salivary duct stone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code K11.5 in GERD & Stomach, Salivary duct stone requires ambulatory pH-impedance monitoring in Salivary duct stone (K11.5: when refractory) so specialists can calibrate treatment intensity against Serum Vitamin B12 in Salivary duct stone (K11.5: & Magnesium (chronic) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Salivary duct stone uses ICD-10 K11.5 across GERD & Stomach specialty care.
- 3 Typical cash cost range: Clinicians assessing Salivary duct stone focus on visceral hypersensitivity [Salivary duct stone K11.5] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Salivary duct stone monitoring tracks Serum Vitamin B12 in Salivary duct stone (K11.5: & Magnesium (chronic) toward B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K11.5).
Ask our AI Specialists anything about Salivary duct stone
What Is Salivary duct stone?
Cataloged under federal diagnostic code K11.5 in GERD & Stomach, Salivary duct stone requires ambulatory pH-impedance monitoring in Salivary duct stone (K11.5: when refractory) so specialists can calibrate treatment intensity against Serum Vitamin B12 in Salivary duct stone (K11.5: & Magnesium (chronic) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Salivary duct stone (K11.5), physiological disruption stems from visceral hypersensitivity [Salivary duct stone K11.5], informing Acid Reflux, GERD & Upper GI Health protocols that track H. pylori Stool in Salivary duct stone (K11.5: Antigen or Urea) (Negative (K11.5)).
Common Symptoms & Clinical Signs
- • Presentation of Salivary duct stone (K11.5): nausea, belching, or in Salivary duct stone (K11.5: discomfort relieved or)
- • Secondary Salivary duct stone clinical sign: post-meal retrosternal heartburn in Salivary duct stone (K11.5: or sour acid)
- • Symptom flares in Salivary duct stone correlating with Serum Vitamin B12 in Salivary duct stone (K11.5: & Magnesium (chronic) deviation outside B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K11.5)
- • Functional gerd & stomach impact requiring ambulatory pH-impedance monitoring in Salivary duct stone (K11.5: when refractory) evaluation (K11.5)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Salivary duct stone Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K11.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Acid Reflux, GERD & Upper GI Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Salivary duct stone (K11.5: & Magnesium (chronic) | B12 > 450 pg/mL; Mg >= 2.0 mg/dL (K11.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: H. pylori Stool in Salivary duct stone (K11.5: Antigen or Urea) | Negative (K11.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin & Serum in Salivary duct stone (K11.5: Ferritin) | Ferritin > 50 ng/mL (no occult loss) (K11.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Salivary duct stone
Treatment selection for Salivary duct stone depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Salivary duct stone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for: What a 980-Participant Study Found This analysis revealed that fosnetupitant could have long-acting antiemetic potency (> 120 h) and indicated the importance of antiemetic therapy at 0-120 h for CINV up to 168 h after chemotherapy. Advances in therapy • 2023-11-15 • Phase III Randomized Trial | N = 980 | 87/100 | PMID 37715851 ↗ |
| What the Latest Evidence Really Says About Associations Between Morning Salivary and Blood Cortisol Concentrations in Cortisol concentrations did not differ between adults with OSAS and healthy controls. Frontiers in endocrinology • 2020-01-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 33542703 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for NEPA plus OLZ with reduced (6 mg day 1 only) or no DEX is noninferior to standard 4-day DEX for chemotherapy-induced nausea and vomiting prevention in HEC, supporting steroid-sparing strategies particularly relevant in the... Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42241642 ↗ |
| Can This Approach Help? Inside the Latest Research on Reducing Salivary Toxicity with Adaptive Radiotherapy The ReSTART trial aims to answer an important question in Radiation Therapy for HNSCC, particularly in a resource-limited setting. Clinical oncology (Royal College of Radiologists (Great Britain)) • 2024-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38575432 ↗ |
| Can This Approach Help? Inside the Latest Research on Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced LEONIDAS-2 did not meet the primary and secondary outcomes. International journal of radiation oncology, biology, physics • 2024-01-01 • Phase III Randomized Trial | N = 86 | 82/100 | PMID 36933846 ↗ |
Salivary duct stone Patient Community & “People Like Me” Threads
Filter Salivary duct stone community threads and patient logs by age, biological sex, dosage, and treatment duration.